AI-aided diagnosis reveals vitamin B6 link in Parkinson's seizures

Ed Patrick sat in a Nottinghamshire hospital in May, watching his mother slip away. Ann Patrick had been deteriorating for months, but the crisis came suddenly—continuous seizures that wouldn't stop, her body convulsing uncontrollably, her kidneys beginning to fail. The medical team had exhausted their options. They had tried every anti-seizure medication available. A registrar called to tell him his mother was dying and asked if he could reach the hospital in time.

Patrick, an anaesthetist from Oxfordshire, arrived to find his mother unconscious and in the grip of relentless fits. The neurologists had run out of answers. So he did something unconventional: he turned to artificial intelligence. Using Google's Gemini tool, he began searching through recent medical journal articles, looking for anything that might explain what was happening to her. What he found was a rare connection—a vitamin B6 deficiency that could be triggered by carbidopa-levodopa, the dopamine-boosting drug his mother had been taking for years to manage her Parkinson's disease. The deficiency, he discovered, could cause exactly the kind of seizures she was experiencing.

He brought this finding to the neurology consultant, Dr. Bruno Gran. The reasoning was sound, Gran later confirmed—Patrick's background in clinical pharmacology gave him the framework to interpret what he'd found. The medical team decided to try something that had never been attempted for Ann: an intravenous dose of vitamin B6. Within minutes of the injection, the seizures stopped. "She hasn't had a seizure since," Patrick said. The next day, he recalled, the neurologist was high-fiving him.

What happened in that hospital room has now become a case that is reshaping how doctors think about Parkinson's treatment. Only 14 similar cases have ever been documented in medical literature worldwide. Yet the U.S. Food and Drug Administration recently issued a memo warning that certain Parkinson's drugs should carry warnings about potential B6 deficiency. The implication is stark: this may not be as rare as the numbers suggest. It may simply be unrecognized.

Ann made a full recovery from the seizures. But the transformation went deeper than that. Her cognitive symptoms—the mental fog and decline that had been creeping in over years—reversed dramatically. "It's like we've got mum back," Patrick said. "She's sharp as a tack." Her day-to-day thinking had improved so much that it was as if she had regained five to ten years of her life. Not long after leaving the hospital, she was well enough to hold her youngest granddaughter and read her a story.

Doctors are now calling for clinical trials to understand the full scope of this connection. Dr. Bruno Gran and his team at Nottingham University Hospitals have already begun changing their practice in response to the case, and the findings have spread to other regional medical teams. The consultant neurologist Prof. Tom Foltynie at University College London Hospitals emphasized that while the link between low B6 and Parkinson's drugs is not yet widely known among NHS staff, it could have significant implications if more patients were routinely tested. About 166,000 people in the UK live with Parkinson's disease.

But experts are also sounding a careful note. Parkinson's UK and other medical organizations have warned patients against making changes to their medications or supplements without consulting their doctors. Excessive vitamin B6 can itself cause problems. Anyone concerned should request a blood test to check their levels before seeking supplementation. The story of Ann Patrick is compelling and her recovery is real, but it is one case—a doorway into a larger question that only rigorous research can answer. What comes next is the slow, methodical work of clinical trials, the kind of research that can turn one family's experience into guidance that might help millions.